Kamran Alam
Finanzdirektor/CFO bei TAYSHA GENE THERAPIES, INC.
Vermögen: 364 313 $ am 30.04.2024
Aktive Positionen von Kamran Alam
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
TAYSHA GENE THERAPIES, INC. | Finanzdirektor/CFO | 01.08.2020 | - |
Unternehmenssekretär | - | - |
Karriereverlauf von Kamran Alam
Ehemalige bekannte Positionen von Kamran Alam
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ROCKET PHARMACEUTICALS, INC. | Finanzdirektor/CFO | 28.10.2019 | 01.07.2020 |
AVEXIS INC | Corporate Officer/Principal | 01.04.2016 | 01.10.2019 |
APTINYX | Comptroller/Controller/Auditor | 01.03.2013 | 01.04.2016 |
Naurex, Inc.
Naurex, Inc. Pharmaceuticals: MajorHealth Technology Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL. | Corporate Officer/Principal | - | - |
Ausbildung von Kamran Alam
Kelley School of Business | Masters Business Admin |
Stephen M. Ross School of Business | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 8 |
Operativ
Director of Finance/CFO | 2 |
Corporate Officer/Principal | 2 |
Masters Business Admin | 1 |
Sektoral
Health Technology | 6 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
ROCKET PHARMACEUTICALS, INC. | Health Technology |
APTINYX | Health Technology |
TAYSHA GENE THERAPIES, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Novartis Gene Therapies, Inc.
Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
Naurex, Inc.
Naurex, Inc. Pharmaceuticals: MajorHealth Technology Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL. | Health Technology |
- Börse
- Insiders
- Kamran Alam
- Erfahrung